At a glance
ClinicalIndex Comparison RecordN/ACompleted· 35 enrolled
Drug / intervention
Sertralinedrug
Likely dose
Sertraline 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Protocol of Self-Controlled Study on the Effects of Sertraline on Depression in Parkinson's Disease
In Brief
A clinical study evaluating Sertraline for Depression and Parkinson's Disease. Completed, enrolled 35 participants across 1 site.
Detailed Summary
The aim of this open-label, self-control study is to evaluate the efficacy of sertraline in treating depression in Patients with Parkinson's disease. In addition, the investigators also want to find out whether patient gets better quality of life when depression is improved.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression, Parkinson's Disease
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
First PostedSep 2011
Primary CompletionAug 2013
Study CompletionNov 2013
TodayJul 2026
First PostedSep 20, 2011
Enrollment StartAug 1, 2011
Primary CompletionAug 1, 2013
Study CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 14.8 years ago
Interventions
Sertralinedrug
Starting dose 25mg/day for 1 week, then increasing to 50mg/day, add on 50mg each time when the depressive symptoms are not improved, at 2-week intervals. Maximum: 200mg/day. Maintenance: lowest effective dose.